International Journal of Virology and Molecular Biology

International Journal of Virology and Molecular Biology interests in all aspects of microbiology in man and animals, especially new trends and advances. It publishes general interest reviews, mini-reviews, experimental and theoretical works and computational analyses in Virology and Molecular Biology and features Wide-ranging coverage of problems related to molecular and cell biology.

Gunnel Halldén

Editorial Board Member of International Journal of Virology and Molecular Biology

Associate Professor, Barts Cancer Insititute, Queen Marys University of London, UK

Research Areas

To Find New Treatments For Cancer By Developing Modified Replication-Selective Adenoviruses As Drugs

Education

2008PGCAPQueen Mary's College, London
1989-1995Ph.DUniversity of California at Berkeley
1978-1984B.S.University of Stockholm and the Karolinska Institute, Stockholm, Sweden

Experience

2004-presentSenior Lecturer and Team Leader in Cancer Gene Therapy Centre for Molecular Oncology
2001-2004 Senior Postdoctoral ScientistViral and Genetic Therapy Program, Molecular Oncology Unit, Cancer Research UK, Imperial College School of Medicine, Hammersmith Hospital, London, UK
2000-2001ScientistAnalytical Development, Onyx Pharmaceuticals, Richmond, California, USA
1997-2000Postdoctoral Researcher Department of Nutritional Sciences & Toxicology, University of California, Berkeley
1996-1997Postdoctoral Researcher Department of Molecular and Cell Biology, and the Cancer Research Laboratory, University of California, Berkeley
1995-1996Postdoctoral Researcher Department of Nutritional Sciences, University of California, Berkeley
1989-1995Ph.D. Graduate Student Graduate Group in Endocrinology, University of California, Berkeley
1988-1989Research Assistant Department of Surgery, University of California, San Francisco
1986-1988 Research AssistantDepartment of Cell Biology, Mount Zion Hospital and Medical Center and University of California, San Francisco
1985-1986Science High School Teacher Kvarnskolan, Jakobsberg, Sweden. Advisor and teacher in mathematics, physics, chemistry and biology
1984-1985Graduate Student Department of Biochemistry II, Karolinska Institute, Stockholm, Sweden, and Department of Psychiatry, Stanford Medical Center, Stanford
1976-1983Research Technician Department of Biochemistry II, Karolinska Institute, Stockholm, Sweden

Membership

American Association for Cancer research (AACR)
American Association for Cell and Gene Therapy (ASGCT)
British Society for Cell and Gene Therapy (BSGCT)
British Association of Research Quality Assurance (BARQA)

Publications: Conferences/Workshops/Symposiums/Journals/Books

[1]  Cherubini G, Kallin C, Mozetic A, Hammaren Busch K, Müller H, Lemoine NR, Halldén G. (2011) The oncolytic adenovirus Ad enhances selective cancer cell killing in combination with DNA damaging drugs in pancreatic cancer models. Gene Ther. In Press.
[2]  Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR, Halldén G. (2011) An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumours in vivo in combination with 5-FU or gemcitabine. Cancer Gene Ther. In Press.
[3]  Radhakrishnan S, Miranda E, Ekblad M, Holford A, Pizarro MT, Lemoine NR, Halldén G. (2010) Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts. Hum Gene Ther. Oct;21(10):1311-25.
[4]  Ingemarsdotter CK, Baird SK, Connell CM, oberg D, Halldén G, McNeish IA. (2010) Low dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene Nov;29(45):6051-63.
[5]  Ekblad M and Halldén G. (2010) Adenovirus-based therapy for prostate cancer. Curr Opin Mol Ther. 12(4):421-31.
[6]  oberg D, Yanover E, Adam V, Sweeney K, Costas C, Lemoine NR, Halldén G. (2010) Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin Cancer Res.16(2):541-53.
[7]  Leitner S, Sweeney K, oberg D, Miranda E, Lemoine NR, Halldén G. (2009) Oncolytic adenoviral mutants with E1B19K-gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumour efficacy in vivo. Clin Cancer Res 15:1730-1740.
[8]  Lee M, Choi S, Halldén G, Yo SJ, Schichnes D, Aponte GW. (2009) P2Y5 is a Gai, Ga12/13 G-Protein Coupled Receptor Activated by Lysophosphatidic Acid that Reduces Intestinal Cell Adhesion. Am J Physiol Gastrointest Liver Physiol. 297(4):G641-54.
[9]  Libertini S, Iacuzzo I, Perruolo G, Scala S, Ieranò C, Franco R, Halldén G, Portella G. (2008) Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947. Clin Cancer Res 14: 6505-6514.
[10]  Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Halldén G, Mautner V, Shen Y, and Seymour LW (2008) Comparison of Molecular Strategies for Breast Cancer Virotherapy using Oncolytic Adenovirus. Hum Gene Ther. In Press, Aug 18, 2008.
[11]  Cheong SC, Wang Y, Meng JH, Hill R, Sweeney K, Kirn D, Lemoine NR, Halldén G (2008) E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther Jan;15(1):40-50.
[12]  Gaballah K, Hills A, Curiel D, Hallden G, Harrison P, Partridge M. (2007) Lysis of dysplastic but not normal oral keratinocytes and tissue-engineered epithelia with conditionally replicating adenoviruses. Cancer Res Aug;67(15):7284-94.
[13]  Choi S, Lee M, Shiu AL, Yo SJ, Halldén G, Aponte GW. (2007) GPR93 activation by protein hydrolysate induces CCK transcription and secretion in STC-1 cells. Am J Physiol Gastrointest Liver Physiol May;292(5):G1366-75.
[14]  Liu T, Wang Y, Halldén G, Brooks G, Francis J, Lemoine N and Kirn D (2005). Functional interactions of anti-apoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. Gene Therapy Sep;12(17):1333-46.
[15]  Wang Y, Thorne S, Hannock J, Lemoine N, Kirn D and Halldén G (2005). A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses. Clin Cancer Research. Jan 1;11(1):351-360.
[16]  Wang Y, Xue SA, Halldén G, Francis J, Yuan M, Griffin BE and Lemoine N (2005). Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors. Cancer Research. Feb. 15;65(4):1523-31.
[17]  Lee L, Hadi M, Halldén G and Aponte GW (2005). PYY and NPY induce villin expression, reduce adhesion, and enhance migration in small intestinal cells through the regulation of CD63, MMP-3 and Cdc42 activity. J Biol Chem Jan 7;280:1:125-136.
[18]  Liu T, Halldén G, Wang Y, Brooks G, Francis J, Lemoine N and Kirn D (2004). An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol Therapy 9:6:786-803.
[19]  Wang Y, Halldén G, Hill R, Anand A, Liu T, Francis J, Brooks G, Lemoine N and Kirn D (2003). E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nature Biotech. 10: 1-8.
[20]  Halldén G, Hill R, Wang Y, Anand A, Liu T, Lemoine N, Francis J, Hawkins L and Kirn D (2003). Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol. Therapy 8:3:412-424.
[21]  Halldén G, Thorne S, Yang J, and Kirn D (2003). Replication-Selective Oncolytic Adenoviruses: Methods and Protocols. In Methods in Molecular Medicine (Humana Press) ed. Caroline Springer, Vol. 90: Suicide Gene Therapy: Methods and Reviews p. 71-90.
[22]  Wang Y, Faux S, Halldén G, Kirn D, Houghton C, Lemoine NR, Patrick G. (2003) Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite. Int J Oncol 25:173-178.
[23]  Kirn D, Niculescu-Duvaz I, Halldén G and Springer CJ (2002). The emerging fields of suicide gene therapy and virotherapy. TRENDS in Mol Med 8:4 (Suppl.):68-73.
[24]  Halldén G, Hadi M, Hong HT and Aponte GW (1999). Y receptor-mediated induction of CD63 transcripts, a tetraspanin determined to be necessary for differentiation of the intestinal epithelial cell line, hBRIE 380i cells. J Biol Chem 274:39:27914-27924.
[25]  Cover CM, Hsieh JS, Tran SH, Halldén G, Kim GS, Bjeldanes LF and Firestone GL (1998). Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 273:7:3838-3847.
[26]  Halldén G. and Aponte G.W. (1997). Evidence for a role of the gut hormone PYY in the regulation of intestinal fatty acid binding protein transcripts in differentiated sub-populations of intestinal epithelial cell hybrids. J. Biol. Chem. 272:19:12591-12600.
[27]  Halldén G, Holehouse E, Dong X and Aponte GW (1994). Expression of intestinal fatty acid binding protein in intestinal epithelial cell lines, hBRIE 380 cells. Am J Phys 267:G730-743.
[28]  Aponte GW, Keddie A, Halldén G, Hess R and Link P (1991). Polarized intestinal hybrid cell lines derived from primary culture: Establishment and characterization. Proc Natl Acad Sci USA 88: 5282-5286.
[29]  Williams JA, Halldén G, McChesney D, Szecowka J, Logsdon CD and Goldfine ID (1990). The cholecystokinin and gastrin receptors. In: Neuropeptides and Their Receptors (Alfred Benzon Symposium 29), edited by T. W. Schwartz, L.M. Hilsted and J.F. Rehfeld. Copenhagen: Munksgaard, p. 310-324.
[30]  Mulvihill SJ, Halldén G and Debas H (1989). Trophic effect of amniotic fluid on cultured fetal gastric mucosal cells. J Surgical Research 46:327-329.
[31]  Szecowka J, Halldén G, Goldfine ID and Williams JA (1988). Purification of the pancreatic cholecystokinin receptor. Regul Pept 24: 215-224.
[32]  Halldén G, Gafvelin G, Mutt V and Jornvall H (1986). Characterization of Cat Insulin. Arch Bioph Bioch 247:1: 20-27.
[33]  Halldén G, Abens J, Engstrom C, Westlind A, Mutt V and Bartfai T (1986). Iodinated derivatives of the vasoactive intestinal polypeptide (VIP) are agonists at the cat pancreas and the rat submandibular salivary gland. Regul Pept 16:183-188.
[34]  Tatemoto K, Jornvall H, Siimesmaa S, Hallden G and Mutt V (1984). Isolation and characterization of cholecystokinin-58 (CCK-58) from porcine brain. Febs Lett 174:1: 289-293.